1. Home
  2. BCHT vs RLYB Comparison

BCHT vs RLYB Comparison

Compare BCHT & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCHT

Birchtech Corp. Common Stock

N/A

Current Price

$1.62

Market Cap

55.0M

Sector

Industrials

ML Signal

N/A

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$8.22

Market Cap

44.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCHT
RLYB
Founded
N/A
2018
Country
United States
United States
Employees
15
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.0M
44.6M
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
BCHT
RLYB
Price
$1.62
$8.22
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
96.2K
76.3K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$858,000.00
Revenue This Year
$13.42
N/A
Revenue Next Year
$61.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$1.61
$0.25
52 Week High
$2.45
$11.49

Technical Indicators

Market Signals
Indicator
BCHT
RLYB
Relative Strength Index (RSI) 30.60 49.52
Support Level N/A $7.90
Resistance Level $2.33 $9.25
Average True Range (ATR) 0.18 0.44
MACD -0.01 -0.12
Stochastic Oscillator 7.06 21.56

Price Performance

Historical Comparison
BCHT
RLYB

About BCHT Birchtech Corp. Common Stock

Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: